Zinc study for sickle cell disease and bone health
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests if taking zinc supplements can improve bone health in people with sickle cell disease. It's for those with certain types of sickle cell disease (SS or S-Beta zero thalassemia) who are not on chronic transfusions or zinc supplements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 15 and 40 years old
- Have sickle cell disease type SS or S-Beta zero thalassemia
- Be in a steady state (no pain crisis for at least 2 weeks)
- Not be taking zinc supplements or be willing to stop for 3 months before the study
- Have vitamin D level of 20 ng/mL or higher
- Not be on chronic blood transfusions (more than 8 per year) or have iron overload
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the drug alendronate can help heal bone damage caused by sickle cell disease. It may be an option if you have this bone problem and are between 18 and 80 years old.
This study looks at how carrying the sickle cell trait (not the disease) affects bone density, physical function, and frailty in older African American women. It aims to help understand bone loss risk and prevent fractures.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
This trial tests early screening and treatment to prevent heart problems in people with sickle cell disease. It focuses on those with high iron levels or heart symptoms, using regular heart imaging to monitor and treat complications early.
This Phase 1 study tests whether nicotinamide, oral tetrahydrouridine, and decitabine can help people with high-risk sickle cell disease. It is mainly a safety-and-dosing study, but it also looks for signs the medicines may improve disease-related problems.
This study tests a medicine called crizanlizumab to see if it helps improve oxygen delivery in people with sickle cell anemia. It may help reduce pain crises and other complications.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.